CARA - Cara Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.46
+0.53 (+3.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close15.93
Open15.96
Bid16.47 x 800
Ask16.60 x 900
Day's Range15.69 - 16.48
52 Week Range8.88 - 27.55
Volume538,850
Avg. Volume568,976
Market Cap770.264M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.44
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Thomson Reuters StreetEvents

    Edited Transcript of CARA earnings conference call or presentation 11-May-20 8:30pm GMT

    Q1 2020 Cara Therapeutics Inc Earnings Call

  • Cara Therapeutics Inc (CARA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Cara Therapeutics Inc (CARA) Q1 2020 Earnings Call Transcript

    This is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics' first quarter 2020 financial results and update conference call. Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements, include statements concerning the expected timing of the data readouts from the Company's ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the Company's product candidates, including the Company's projected timeline for the submission of its first NDA, the potential for the Company's product candidates to be alternatives in the therapeutic areas investigated, and the Company's expected cash reach.

  • Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cara Therapeutics Reports First Quarter 2020 Financial Results

    STAMFORD, Conn., May 11, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.

  • GlobeNewswire

    Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

    STAMFORD, Conn., May 07, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.

  • GlobeNewswire

    Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

    STAMFORD, Conn., May 04, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.

  • Better Buy: Cara Therapeutics vs. Sangamo Therapeutics
    Motley Fool

    Better Buy: Cara Therapeutics vs. Sangamo Therapeutics

    Take Cara Therapeutics (NASDAQ: CARA) and Sangamo Therapeutics (NASDAQ: SGMO), for example. One thing that both Cara and Sangamo have in common, though, are promising pipeline candidates. Investors have placed a greater value on Sangamo's pipeline based on the company's higher market cap.

  • Will Cara Therapeutics (NASDAQ:CARA) Spend Its Cash Wisely?
    Simply Wall St.

    Will Cara Therapeutics (NASDAQ:CARA) Spend Its Cash Wisely?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline
    Zacks

    Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline

    Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Cara Therapeutics' Shares March Higher, Can It Continue?
    Zacks

    Cara Therapeutics' Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Cara Therapeutics.

  • GlobeNewswire

    Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus

    Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo.

  • Top Marijuana Stocks for April 2020
    Investopedia

    Top Marijuana Stocks for April 2020

    The marijuana industry is made up of companies that either support or are engaged in the research, development, distribution, and sale of medical and recreational marijuana. Marijuana stocks, as represented by the ETFMG Alternative Harvest ETF (MJ), have dramatically underperformed the broader market, posting a total return of -66.5% compared to 0.9% for the S&P 500 over the past 12 months. These market performance numbers and the statistics in the tables below are as of April 17. Here are the top 3 marijuana stocks with the best value, the fastest sales growth, and the most momentum.

  • Top Marijuana Stocks on the NASDAQ for April 2020
    Investopedia

    Top Marijuana Stocks on the NASDAQ for April 2020

    These are the NASDAQ-listed marijuana stocks with the best value, fastest growth, and most momentum for April.

  • GlobeNewswire

    Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

    STAMFORD, Conn., April 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed.

  • GlobeNewswire

    Cara Therapeutics Reports Clinical Updates

    - On track to report topline data for KALM-2 Phase 3 global trial of  KORSUVA™ Injection in second quarter –                    - On track to complete interim statistical.

  • Thomson Reuters StreetEvents

    Edited Transcript of CARA earnings conference call or presentation 27-Feb-20 9:30pm GMT

    Q4 2019 Cara Therapeutics Inc Earnings Call

  • 3 Beaten-Down Biotech Stocks With Catalysts Just Around the Corner
    TipRanks

    3 Beaten-Down Biotech Stocks With Catalysts Just Around the Corner

    With the outbreak of the coronavirus, volatility has become a seemingly ever-present facet of the stock market. Since the end of February, the major U.S. indexes have experienced violent swings in either direction, with these movements culminating in a circuit breaker being triggered on March 9 after the S&P 500 slipped by over 7%.While the current economic landscape has spurred fear among investors, others view market volatility as a possible avenue to huge rewards. Pointing to the healthcare sector specifically, those ready to take on some risk cite the potential returns that can be delivered should a name inhabiting this space release positive data or receive FDA approval. As healthcare companies generally rely on these few key indicators, the results can either send shares skyrocketing or down the drain.Bearing this in mind, we used TipRanks’ Stock Screener to identify three beaten-down biotech stocks that have significant catalysts coming up. The tool not only revealed that each of these Buy-rated tickers has attracted significant praise from analysts, all three also boast lofty upside potential. Here’s the scoop.MyoKardia Inc. (MYOK)This biotech name specializes in developing cutting-edge therapies for orphan cardiovascular diseases like hypertrophic obstructive and non-obstructive cardiomyopathy as well as dilated cardiomyopathy. Despite the year-to-date hit shares have taken, analysts are betting on MyoKardia ahead of an important data readout.During the second quarter of 2020, the company is expected to release data from the Phase 3 EXPLORER trial, which is evaluating its mavacamten therapy in patients with obstructive hypertrophic cardiomyopathy (oHCM). Management stated in its Q4 earnings call that 50% of oHCM patients are treated by 2,800 cardiologists, and the company is planning on targeting this physician group. Additionally, the HCM awareness campaign, which began in November, also stands to benefit MYOK by increasing awareness of the disease, with a new online resource being added for doctors this spring.For BMO Capital’s George Farmer, the previous mavacamten data is what has him excited about MYOK’s prospects. “We believe the primary endpoint will be met in EXPLORER for the following reasons: (1) the unprecedented efficacy profile with improved pVO2 and NYHA achieved with mavacamten in PIONEER sustained over 48 weeks; (2) the attractive mavacamten safety profile that emerged from the placebo-controlled nHCM MAVERICK trial (note here); and (3) the apparent utility of monitoring LVOT gradient in order to achieve optimal dosing in the oHCM treatment setting,” the analyst explained.While Farmer added that the impact of mavacamten on left ventricular ejection fraction (LVEF) has been a cause for concern, he argues that the trial’s design to include careful dose-titration could reduce some of the risk.To this end, the five-star analyst stays with the bulls, reiterating his Outperform rating. Along with the call, the assigned $90 price target implies that shares could climb 57% higher in the next year. (To watch Farmer’s track record, click here)What does the rest of the Street have to say? It turns out all 7 analysts that have published a recent review see the stock as a Buy, making the consensus rating a Strong Buy. At $85.83, the average price target implies 50% upside potential. (See MyoKardia stock analysis on TipRanks)Cara Therapeutics (CARA)By developing a class of peripherally acting kappa opioid agonist therapies, Cara Therapeutics is hoping to provide a more effective treatment option for chronic pruritis (itchy skin). While Cara shares tumbled nearly 17% year-to-date, some biotech pros see the upcoming top-line KALM-2 efficacy data release as being a major turning point.Back in October, the healthcare company increased the patient enrollment for the study by 20% to 430 patients at the request of an Independent Data Monitoring Committee (IDMC). KALM-2 is the second of two trials looking at the intravenous (IV) form of its CR845 drug in hemodialysis patients with chronic kidney disease (CKD)-associated pruritis, the results of which are slated for a Q2 2020 announcement.Weighing in on CARA for Piper Sandler, analyst David Amsellem explains that the increase in the number of patients was likely due to the fact that the KALM-2 study has more patient variability because its sites are located in multiple countries, while KALM-1 was only in the U.S. “Given that CR845 was highly statistically superior to placebo in the KALM-1 study (to the tune of a very strong p-value of .000019) and that KALM-2 has essentially the same design as KALM-1 (refer to our note on 10/14/19 for more details), we would be surprised to see results from KALM-2 diverge dramatically from KALM-1,” the analyst commented.On top of this, Amsellem also highlights the oral form of the candidate as setting the company up for serious growth. While oral CR845 failed to impress in its Phase 2 study as it missed on a responder analysis at week 12, a large and “well-powered” pivotal study could go a long way for CARA. With this in mind, Amsellem stated, “We continue to believe that both the IV and oral forms of CR845 will reach the market, driving a potentially $1 billion-plus franchise and hence transformative value creation.”In line with his optimistic approach, Amsellem left his Overweight call and $39 price target intact. Should this target be met, a twelve-month gain of 187% could be in the cards. (To watch Amsellem’s track record, click here)Judging by the consensus breakdown, the analyst communitity is on the same page. Given that 4 Buys have been issued in the last three months compared to no Holds or Sells, the message is clear: CARA is a Strong Buy. While less aggressive than Amsellem’s forecast, the $33.50 average price target still suggests 148% upside potential. (See Cara stock analysis on TipRanks)Eloxx Pharmaceuticals (ELOX)With the goal of treating rare and ultra-rare premature stop codon diseases, Eloxx has become one of the leaders in the eukaryotic ribosomal selective glycosides (ERSG) space. Even though shares suffered a beating after cystinosis data for its already approved Procysbi product was released last month, Janney analyst Yun Zhong sees a key upcoming catalyst related to its investigational candidate, ELX-02, as capable of driving a turnaround.Zhong points out that each of the three patients in the low-dose cohort from Procysbi's clinical study had gone through renal transplantation, with the result indicating that data interpretation from transplant patients could be difficult. In his opinion, this makes the recent sell-off of ELOX “overdone”. The analyst added, “We believe Eloxx will modify the protocol after the ongoing data review with cystinosis experts and we believe a higher dose and a younger patient population could lead to improved efficacy.”Additionally, Zhong thinks the top-line data readout for the Phase 2 study of ELX-02 in cystic fibrosis (CF) in first half of 2020 represents a significant catalyst, stating that he doesn’t believe there will be a readthrough from the Procysbi results. It should be noted that the CF program features two Phase 2 open-label studies located in the U.S. and Israel.With patient enrollment expected to wrap up in the first quarter of 2020, Zhong believes a positive outcome is likely. “Based on data from the Phase II study of Kalydeco in CF patients with the G551D mutation, we believe a reasonable expectation would be to see a meaningful change from baseline in sweat chloride, which will serve as the primary biomarker for ELX-02 dose selection for pivotal studies,” he commented.This reduction in sweat chloride is essential as it could allow the candidate to progress to a pivotal Phase. Taking all of this into consideration, Zhong recommends snapping up shares on recent weakness. Along with a Buy rating, he puts a $14 price target on the stock. This conveys his confidence in ELOX’s ability to soar 344% in the next twelve months. (To watch Zhong’s track record, click here)Turning now to the analyst community, a Moderate Buy consensus rating breaks down into 2 Buys and a single Hold. Given its $10.33 average price target, the upside potential comes in at 232%. (See Eloxx stock analysis on TipRanks)

  • Cara Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
    Simply Wall St.

    Cara Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates

    There's been a notable change in appetite for Cara Therapeutics, Inc. (NASDAQ:CARA) shares in the week since its...

  • Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of 1.61% and -19.13%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

    STAMFORD, Conn., Feb. 27, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed.

  • GlobeNewswire

    Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

    STAMFORD, Conn., Feb. 20, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.

  • Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Salary Reflect Performance?
    Simply Wall St.

    Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Salary Reflect Performance?

    In 2004 Derek Chalmers was appointed CEO of Cara Therapeutics, Inc. (NASDAQ:CARA). First, this article will compare...

  • New Cannabis Products Which Could Disrupt the Industry in 2020
    Investopedia

    New Cannabis Products Which Could Disrupt the Industry in 2020

    The cannabis industry enjoyed tremendous investor enthusiasm in 2018, fueled in large part by major developments which seemed to open up the space for new opportunities. In spite of the fact that cannabis stocks overall failed to perform up to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry. If cannabis stocks are to thrive going forward, it's likely that many companies will have some growing up to do.

  • GlobeNewswire

    Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    STAMFORD, Conn., Jan. 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.